432. Larkin J., Lao C. D., Urba W. J., McDermott D. F., Horak C., Jiang J., Wolchok J. D. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials // JAMA Oncol. ‒ 2015. ‒ T. 1, № 4. ‒ C. 433-40.
433. Kreft S., Gesierich A., Eigentler T., Franklin C., Valpione S., Ugurel S., Utikal J., Haferkamp S., Blank C., Larkin J., Garbe C., Schadendorf D., Lorigan P., Schilling B. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma // Eur J Cancer. ‒ 2019. ‒ T. 116. ‒ C. 207-215.
434. Administration U. S. F. a. D. Modification of the Dosage Regimen for Nivolumab. ‒ 2016. ‒ URL: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm520871.htm.
435. Fogt S., Shustova M., Demidov L. V., Moiseyenko V., Tjulandin S., Semiglazova T., Protsenko S., Odintsova S., Zukov R., Lazarev S., Makarova Y., Nechaeva M., Sakaeva D., Andreev A., Tarasova A., Fadeeva N., Gavrilova O., Ivanov R. Phase II trial (BCD-100-2/MIRACULUM) of the novel PD-1 inhibitor (BCD-100) in patients with advanced melanoma // Journal of Clinical Oncology. ‒ 2019. ‒ T. 37, № 15_suppl. ‒ C. 9549-9549.
436. Tjulandin S., Fedyanin M., Demidov L., Moiseyenko V., Protsenko S., Odintsova S., Semiglazova T. Y., Zukov R., Lazarev S., Andreev A., Nechaeva M., Makarova J., Fadeeva N., Tarasova A., Kozlova O., Shustova M., Garipov A., Ivanov R. FINAL RESULTS OF PHASE II TRIAL (MIRACULUM) OF THE NOVEL PD-1 INHIBITOR PROLGOLIMAB IN PATIENTS WITH ADVANCED MELANOMA // Annals of Oncology. ‒ 2019. ‒ T. 30. ‒ C. xi33-xi47.
437. Lebbe C., Meyer N., Mortier L., Marquez-Rodas I., Robert C., Rutkowski P., Menzies A. M., Eigentler T., Ascierto P. A., Smylie M., Schadendorf D., Ajaz M., Svane I. M., Gonzalez R., Rollin L., Lord-Bessen J., Saci A., Grigoryeva E., Pigozzo J. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial // J Clin Oncol. ‒ 2019. ‒ T. 37, № 11. ‒ C. 867-875.
438. Olson D. J., Eroglu Z., Brockstein B., Poklepovic A. S., Bajaj M., Babu S., Hallmeyer S., Velasco M., Lutzky J., Higgs E., Bao R., Carll T. C., Labadie B., Krausz T., Zha Y., Karrison T., Sondak V. K., Gajewski T. F., Khushalani N. I., Luke J. J. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma // J Clin Oncol. ‒ 2021. ‒ T. 39, № 24. ‒ C. 2647-2655.
439. Yang H., Higgins B., Kolinsky K., Packman K., Go Z., Iyer R., Kolis S., Zhao S., Lee R., Grippo J. F., Schostack K., Simcox M. E., Heimbrook D., Bollag G., Su F. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models // Cancer Res. ‒ 2010. ‒ T. 70, № 13. ‒ C. 5518-27.
440. Johnson D. B., Menzies A. M., Zimmer L., Eroglu Z., Ye F., Zhao S., Rizos H., Sucker A., Scolyer R. A., Gutzmer R., Gogas H., Kefford R. F., Thompson J. F., Becker J. C., Berking C., Egberts F., Loquai C., Goldinger S. M., Pupo G. M., Hugo W., Kong X., Garraway L. A., Sosman J. A., Ribas A., Lo R. S., Long G. V., Schadendorf D. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms // Eur J Cancer. ‒ 2015. ‒ T. 51, № 18. ‒ C. 2792-9.
441. Network N. C. C. Melanoma: Cutaneous (Version 2.2025). ‒ 2025. ‒ URL: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf (дата обращения: 30.04.2025.
442. Zimmer L., Apuri S., Eroglu Z., Kottschade L. A., Forschner A., Gutzmer R., Schlaak M., Heinzerling L., Krackhardt A. M., Loquai C., Markovic S. N., Joseph R. W., Markey K., Utikal J. S., Weishaupt C., Goldinger S. M., Sondak V. K., Zager J. S., Schadendorf D., Khushalani N. I. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma // Eur J Cancer. ‒ 2017. ‒ T. 75. ‒ C. 47-55.
443. Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., van den Eertwegh A. J., Lutzky J., Lorigan P., Vaubel J. M., Linette G. P., Hogg D., Ottensmeier C. H., Lebbe C., Peschel C., Quirt I., Clark J. I., Wolchok J. D., Weber J. S., Tian J., Yellin M. J., Nichol G. M., Hoos A., Urba W. J. Improved survival with ipilimumab in patients with metastatic melanoma // N Engl J Med. ‒ 2010. ‒ T. 363, № 8. ‒ C. 711-23.
444. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., Lebbe C., Baurain J. F., Testori A., Grob J. J., Davidson N., Richards J., Maio M., Hauschild A., Miller W. H., Jr., Gascon P., Lotem M., Harmankaya K., Ibrahim R., Francis S., Chen T. T., Humphrey R., Hoos A., Wolchok J. D. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma // N Engl J Med. ‒ 2011. ‒ T. 364, № 26. ‒ C. 2517-26.
445. Самойленко И. В., Харкевич Г. Ю., Демидов Л. В. ПРИМЕНЕНИЕ БЛОКАТОРА РЕЦЕПТОРОВ CTLA4 В ЛЕЧЕНИИ БОЛЬНЫХ МЕТАСТАТИЧЕСКОЙ МЕЛАНОМОЙ // РОССИЙСКИЙ МЕДИЦИНСКИЙ ЖУРНАЛ ‒2015. ‒ T. 21, № 1. ‒ C. 4-9.
446. Li J., Gu J. Efficacy and safety of ipilimumab for treating advanced melanoma: A systematic review and meta-analysis // J Clin Pharm Ther. ‒ 2019. ‒ T. 44, № 3. ‒ C. 420-429.
447. Zhang S., Liang F., Li W., Wang Q. Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis // Eur J Cancer. ‒ 2017. ‒ T. 83. ‒ C. 71-79.
448. Robert C., Ribas A., Schachter J., Arance A., Grob J. J., Mortier L., Daud A., Carlino M. S., McNeil C. M., Lotem M., Larkin J. M. G., Lorigan P., Neyns B., Blank C. U., Petrella T. M., Hamid O., Su S. C., Krepler C., Ibrahim N., Long G. V. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study // Lancet Oncol. ‒ 2019. ‒ T. 20, № 9. ‒ C. 1239-1251.